Stock Traders Buy High Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of unusually large options trading activity on Tuesday. Traders purchased 140,688 call options on the company. This is an increase of approximately 504% compared to the typical volume of 23,306 call options.

Analyst Ratings Changes

TEVA has been the subject of a number of recent analyst reports. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, Barclays upped their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insider Buying and Selling

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC lifted its stake in shares of Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its stake in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after purchasing an additional 2,204,623 shares in the last quarter. State Street Corp increased its position in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after purchasing an additional 1,778,268 shares during the period. Geode Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock worth $157,571,000 after buying an additional 291,124 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after buying an additional 1,031,400 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $20.88 on Wednesday. The company has a 50-day moving average price of $17.47 and a two-hundred day moving average price of $17.40. Teva Pharmaceutical Industries has a 52 week low of $10.00 and a 52 week high of $21.05. The stock has a market cap of $23.66 billion, a price-to-earnings ratio of -23.21, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.